

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

November 2016
Volume 19, Number 11

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Highlights of Changes in Protocols, PPOs and Patient Handouts** – Delisting of UGOTDHR
- **Provincial Systemic Therapy Program** – Revised Policies
- **Nursing Update** – New Online Immunotherapy Toolkit – Checkpoint Inhibitors
- **Continuing Education Corner** – Genitourinary Cancer Update (GUCU) 2016
- **Cancer Drug Manual** – Revised: Panitumumab
- **Benefit Drug List** – Revised: LUAVAFAT, LUAVGEFF, LUOTPAC; Delisted: UGOTDHR
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: GUPDOC; Revised: BRAJTAM, CNAJTZRT, CNMODPCV, CNTEMOZ, GIAVPANI, GICOXB, GOOVAI, GOOVTAM, GUEDPM, LUAVAFAT, ULUAVCRIZ, ULUAVCRIZF, LUAVDC, LUAVDOC, LUAVERL, LUAVGEFF, LUAVMTNE, LUAVNP, LUAVPC, LUAVPEM, LUAVPG, ULUAVPMTN, LUAVPP, LUAVVIN, LUOTPAC, LYIVACR, UMYCTD, UMYLENDEX, UMYLENMTN, UMYMPT, UMYPOMDEX, UMYTHALID, USMAVDT; Deleted: UGOTDHR
- **Website Resources and Contact Information**

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PPOs AND PATIENT HANDOUTS

DELISTING OF UGOTDHR

Gynecologic Malignancies:

In the [August 2016 issue](#) of the Systemic Therapy Update, the BCCA Gynecologic Malignancies Tumour Group announced the approval of GOTDEMACO* to replace UGOTDHR** as the treatment standard for high-risk gestational trophoblastic neoplasia. As such, UGOTDHR will now be removed from the BCCA Benefit Drug List.

* GOTDEMACO – Etoposide, Methotrexate, Leucovorin (Folinic Acid), Dactinomycin, Cyclophosphamide and Vincristine (also known as the “EMA-CO” protocol)

** UGOTDHR – Cisplatin, Etoposide, Dactinomycin, Methotrexate and Leucovorin (also known as the “MACE” protocol)

PROVINCIAL SYSTEMIC THERAPY PROGRAM

REVISED POLICIES

Effective immediately, the BCCA Benefit Drug List has eliminated the “Class II” category. All benefit drugs that were previously classified as “Class II” have been reclassified to “Class I”. As such, the following [Provincial Systemic Therapy Program Policies](#) have been revised to remove the reference to Class II benefit drugs:

- III-10 Systemic Therapy Treatment Delivery Process
- III-40 Systemic Therapy Treatments
- III-45 Compassionate Access Program

Over the past several months, the BCCA Benefit Drug List, the Patient Assistance Programs document, and all affected chemotherapy treatment protocols and PPPOs have also been revised to reflect this change.

NURSING UPDATE

NEW ONLINE IMMUNOTHERAPY TOOLKIT – CHECKPOINT INHIBITORS

Checkpoint inhibitors are being increasingly recognised as effective treatments against cancer. It is also recognized that these novel agents have side effect profiles that are quite unique from those of traditional cytotoxic chemotherapy agents. A new **Nursing Immunotherapy Toolkit** has been developed and made available on the [BCCA Nursing website](#). This toolkit contains the following resources to prepare, guide and support Registered Nurses (RNs) of British Columbia to provide care to patients receiving novel immunotherapy agents, namely checkpoint inhibitors (i.e. ipilimumab, nivolumab, pembrolizumab).

- An online learning module on checkpoint inhibitors and the management of immune-related adverse events (irAEs)
- A recommended Immunotherapy Nursing Process to guide nurses in the patient assessment and documentation process
- Nursing resources related to the management of irAEs
- Patient education resources

BCCA Nursing welcomes any feedback, questions or suggestions about the Toolkit, which can be directed to: nursinged@bccancer.bc.ca or 604-877-6000 (Ext. 672638).

CONTINUING EDUCATION CORNER

GENITOURINARY CANCER UPDATE (GUCU) 2016

Date: November 18-19, 2016
Location: Rosewood, Hotel Georgia, Downtown Vancouver, BC
Website: www.gucu.ca
Registration: \$100 (Physicians), \$50 (Allied Health Professionals & Residents)

The 2016 BCCA Provincial Multidisciplinary GU Tumour Group Meeting aims to present practical perspectives on the treatment of GU cancers – prostate, kidney, bladder, and testis. The conference will include case-based reviews and lectures by BCCA physicians and internationally recognized keynote speakers. For further information about the conference and its agenda, please visit the conference website noted above.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Panitumumab Monograph:

- *Parenteral Administration* – clarified duration of intermittent infusion

BENEFIT DRUG LIST

REVISED PROGRAMS

Effective 1 November 2016, the following BCCA treatment programs have been revised on the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib	LUAVAFAT	Class I (from Restricted)
First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib	LUAVGEFF	Class I (from Restricted)
Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide	LUOTPAC	Class I (from Restricted)

BENEFIT DRUG LIST

DELISTED PROGRAMS

Effective 1 November 2016, the following BCCA treatment program has been removed from the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Therapy for High-Risk Gestational Trophoblastic Cancer (based on GO9103 "MACE" Protocol) using CISplatin, Etoposide, Dactinomycin, Methotrexate and Leucovorin	UGOTDHR	Restricted

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GUPDOC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic Hormone Refractory Prostate Cancer Using DOCEtaxel

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJTAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Tamoxifen
CNAJZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
CNMODPCV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	For Modified PCV Chemotherapy of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vinCRISTine
CNTEMOZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Therapy for Malignant Brain Tumours using Temozolomide
GIAVPANI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Infusion rate and dermatologic toxicities updated; TALLman lettering formatted</i>	Palliative Third-Line Treatment of Metastatic Colorectal Cancer using PANitumumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GICOXB	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>IV line flushing added to oxaliplatin infusion</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine
GOOVAI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Typo corrected in footer</i>	Therapy for Advanced Ovarian Cancer using an Aromatase Inhibitor
GOOVTAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Exclusions clarified</i>	Therapy for Advanced Ovarian Cancer using Tamoxifen
GUEDPM	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Typo corrected re: aprepitant dosing schedule</i>	Treatment of Metastatic Adrenocortical Cancer with Etoposide, DOXOrubicin, CISplatin and Mitotane
LUAVAFAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; CAP requirement removed from Eligibility; Protocol Code updated</i>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib
ULUAVCRIZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional</i>	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
ULUAVCRIZF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional</i>	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
LUAVDC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and DOCEtaxel
LUAVDOC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Protocol Title and Eligibility clarified; C-reactive protein monitoring changed to optional</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with DOCEtaxel
LUAVERL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer with Erlotinib
LUAVGEFF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; CAP requirement removed from Eligibility; Protocol Code updated</i>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib
LUAVMTNE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Reference to gefitinib protocol updated</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib after First-Line Chemotherapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LUAVNP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and Vinorelbine
LUAVPC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CARBOplatin and PACLitaxel
LUAVPEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional, treatment duration clarified</i>	Second-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pemetrexed
LUAVPG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine
ULUAVPMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration clarified</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed
LUAVPP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Pemetrexed
LUAVVIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>C-reactive protein monitoring changed to optional; Test requirements and reference to gefitinib protocol updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Vinorelbine in Elderly Patients
LUOTPAC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement removed from Eligibility; Protocol Code updated</i>	Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide
LYIVACR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Signature space for intrathecal administration added</i>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab
UMYCTD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated</i>	Treatment of Systemic Light-chain (AL) Amyloidosis and Multiple Myeloma using Cyclophosphamide, Thalidomide and Dexamethasone
UMYLENEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated, liver function tests standardized, melphalan option deleted</i>	Therapy of Multiple Myeloma using Lenalidomide with Dexamethasone

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UMYLENMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated, liver function tests standardized</i>	Maintenance Therapy of Multiple Myeloma using Lenalidomide
UMYMPT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Thalidomide
UMYPOMDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated</i>	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone
UMYTHALID	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Pregnancy tests updated</i>	Therapy of Multiple Myeloma using Thalidomide
USMAVDT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Supply quantity updated</i>	Treatment of BRAF V600 Mutation Positive Unresectable or Metastatic Melanoma Using daBRAFeinib and Trametinib

DELETED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UGOTDHR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Therapy for High-Risk Gestational Trophoblastic Cancer (based on GO9103 "MACE" Protocol) using CISplatin, Etoposide, Dactinomycin, Methotrexate and Leucovorin

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Lorraine Leitz, MLS
 Ava Hatcher, RN, BN CONc
 Rob Watt, BSc(Pharm)